Anzeige
Mehr »
Dienstag, 17.02.2026 - Börsentäglich über 12.000 News
Bio-Milliardenmarkt: Steht Organto vor der Neubewertung?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
189 Leser
Artikel bewerten:
(1)

Heart Attack Diagnostics Market to Reach $21.1 Billion, Globally, by 2033 at 8.6% CAGR: Allied Market Research

The global heart attack diagnostics market is experiencing growth due to several factors such as increase in prevalence of cardiovascular diseases, technological advancement in diagnostic techniques, and rise in awareness among both healthcare providers and patients about the importance of early detection and intervention in preventing adverse outcomes from heart attacks.

WILMINGTON, Del., Feb. 17, 2026 /PRNewswire/ -- Allied Market Research published a report, titled, "Heart Attack Diagnostics Market by Type (Electrocardiogram, Blood Tests, Angiogram, Computerized Cardiac Tomography and Others), and End User (Hospitals, Diagnostics Centers, and Others): Global Opportunity Analysis and Industry Forecast, 2024-2033". According to the report, the heart attack diagnostics market was valued at $9.2 billion in 2023, and is estimated to reach $21.1 billion by 2033, growing at a CAGR of 8.6% from 2024 to 2033.

Allied Market Research Logo

Request Sample of the Report on Global Heart Attack Diagnostics Market 2033 - https://www.alliedmarketresearch.com/request-sample/A12689

Prime determinants of growth

The heart attack diagnostics market is experiencing significant growth driven by advancements in medical imaging technologies. For instance, the adoption of advanced imaging modalities allows healthcare professionals to visualize heart anatomy and blood flow with exceptional detail, facilitating prompt diagnosis and treatment decisions. Furthermore, the rise in prevalence of lifestyle-related risk factors, such as obesity, sedentary lifestyles, and unhealthy dietary habits, contributes to an increased incidence of heart attacks globally.

Thus, there is a rise in demand for innovative diagnostic solutions capable of identifying individuals at high risk of cardiac events and guiding personalized interventions to mitigate these risks. Moreover, the increase in adoption of telemedicine and remote monitoring solutions has expanded access to cardiac diagnostic services, particularly in underserved rural areas and remote regions. Remote monitoring devices, such as wearable ECG monitors and smartphone-based cardiac apps, enable patients to self-monitor their heart health and transmit real-time data to healthcare providers for timely assessment and intervention, thereby facilitating early detection and management of heart attacks.

Report coverage & details:

Report Coverage

Details

Forecast Period

2024-2033

Base Year

2023

Market Size in 2022

$9.2 Billion

Market Size in 2032

$21.1 Billion

CAGR

8.60 %

No. of Pages in Report

260

Segments Covered

Type, End User and Region.

Drivers

Advancements in Medical Imaging Technologies


Increase in Prevalence of Cardiovascular Disease


Adoption of Telemedicine and Remote Monitoring Solutions

Opportunities

Technological Innovations and Product Development


Market Expansion in Emerging Economies


Focus on Personalized Medicine

Restraint

High Cost of Advanced Diagnostic Technologies

Want to Explore More, Connect to our Analyst - https://www.alliedmarketresearch.com/connect-to-analyst/A12689

Who Are the Key Players in the Market and What Are Their Strategies?

Key players that shape the competitive landscape include Abbott Laboratories, Siemens Healthineers, F. Hoffmann-La Roche Ltd., GE Healthcare, Philips Healthcare, Bio-Rad Laboratories, Beckman Coulter (Danaher), Bionet Co., Ltd., Schiller AG, Hitachi Medical Systems, and others.

Abbott Laboratories, a major diagnostic company, focuses on strengthening its cardiac biomarker portfolio and enhancing point-of-care testing solutions that deliver fast, accurate results for emergency settings.

Siemens Healthineers prioritizes integration of advanced imaging and analytical capabilities. Its product strategy includes high-resolution CT and MRI systems coupled with AI-assisted diagnostic software to support precise detection of heart damage. Siemens also focuses on tailored solutions for large hospitals and tertiary care centers where multi-modal diagnostics are critical.

F. Hoffmann-La Roche Ltd. (Roche Diagnostics) continues to invest in laboratory-based and POC cardiac biomarker tests, including enhancements to its Elecsys troponin and NT-proBNP assays. These tests aid clinicians in both acute diagnosis and management of cardiac conditions.

GE Healthcare competes with a strong portfolio of portable ECG devices and emergency-focused diagnostic tools, supporting rapid assessment in both hospital and remote settings. Its strategy includes partnerships with telehealth and emergency responders to extend diagnostic reach.

How Intense Is Market Competition and What Defines Competitive Advantage?

Competition in the heart attack diagnostics market is moderately intense, with performance driven by innovation, clinical reliability, and strategic positioning of products and services. The competitive landscape is shaped by multiple product types including electrocardiogram (ECG) systems, blood biomarker tests (notably high-sensitivity troponin assays), computerized cardiac tomography, and angiography tools-each targeting specific clinical needs.

A major factor defining competitive advantage is technological innovation. Companies that deliver rapid, accurate diagnostics with strong clinical evidence tend to stand out. Product portfolio also strengthens competitive position. Firms like Abbott, Roche, Siemens, and GE Healthcare offer a range of diagnostic tools. Integrated solutions that combine biomarkers, imaging, and analytics are in demand because they support streamlined clinical workflows and improved patient outcomes.

North America to maintain its dominance by 2033

By region, North America held the largest market share in terms of revenue in 2023 and is expected to dominate the market during the forecast period. This is attributed to its advanced technology infrastructure, strong demand & availability of heart attack diagnostic devices, supportive regulatory environment, and collaborative ecosystem fostering innovation and market growth in the market. However, the Asia-Pacific region is expected to witness the highest growth during the forecast period.

In developing countries such as China and India, the heart attack diagnostics market presents unique opportunities driven by several factors such as high burden of cardiovascular diseases due to a combination of demographic, socio-economic, and lifestyle factors. In addition, the rapid expansion of healthcare infrastructure and increase in focus on improving access to quality healthcare services present significant opportunities for market growth.

Key Players

  • Bionet Co. Ltd.
  • Toshiba Corporation
  • Bio-Rad Laboratories Inc.
  • Life Sign LLC Schiller AG
  • Beckman Coulter
  • GE Healthcare
  • Hitachi Medical Systems
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories

The report provides a detailed analysis of these key players in the global heart attack diagnostics market. These players have adopted different strategies such as new product launches, collaborations, expansion, joint ventures, agreements, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

We offer customized report as per your requirement: https://www.alliedmarketresearch.com/request-for-customization/A12689

Recent Development

  • In February 2023, Cardio Diagnostics Holdings launched PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.
  • In April 2021, Roche launched a series of five new intended uses for two key cardiac biomarkers using the Elecsys technology: highly sensitive cardiac troponin T (cTnThs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks (cTnT-hs) and better manage heart failure (NT-proBNP).
  • In March 2021, the European Union approved the artificial intelligence-based CaRi-Heart Technology to detect and predict the risk of severe heart attack years before it happens. The CaRi-Heart Technology was developed by the British Heart Foundation and Caristo Diagnostics.

Trending Reports in Healthcare Industry:

Intermittent Catheters Market - Global Opportunity Analysis and Industry Forecast, 2024-2033

Molecular Spectroscopy Market - Global Opportunity Analysis and Industry Forecast, 2024-2035

Wound Irrigation System Market - Global Opportunity Analysis and Industry Forecast, 2024-2035

Herb Extract Market - Global Opportunity Analysis and Industry Forecast, 2024-2035

Cardiovascular Diagnostic Device Market - Global Opportunity Analysis and Industry Forecast, 2024-2035

Boxcar Scars Market - Global Opportunity Analysis and Industry Forecast, 2024-2035

Metered Dose Inhalers Market - Global Opportunity Analysis and Industry Forecast, 2024-2035

Intracardiac Echocardiography Devices Market - Global Opportunity Analysis and Industry Forecast, 2024-2035

Alcoholic Hepatitis Treatment Market - Global Opportunity Analysis and Industry Forecast, 2024-2035

Bariatric Beds Market - Global Opportunity Analysis and Industry Forecast, 2024-2035

AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail themselves of an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Get access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients in making strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies, and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality data and help clients in every way possible to achieve success. Each data presented in the reports published by us is extracted through primary interviews with top officials from leading companies in the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact

David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int'l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com

Logo - https://mma.prnewswire.com/media/636519/5801115/Allied_Market_Research_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/heart-attack-diagnostics-market-to-reach-21-1-billion-globally-by-2033-at-8-6-cagr-allied-market-research-302689626.html

© 2026 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.